BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioMarin Pharmaceutical Inc. (BMRN) Healthcare & Pipeline Overview

BioMarin Pharmaceutical Inc. specializes in developing and commercializing therapies for rare genetic diseases, offering treatments like enzyme replacement therapies and gene therapies. With a focus on unmet medical needs, BioMarin serves a global patient base, holding a significant position in the biotechnology sector with a $12.7B market cap.

What Is the Investment Thesis for BMRN?

With a P/E ratio of 40.23 and a profit margin of 8.3%, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of existing products like Voxzogo and Palynziq, as well as the potential approval and launch of valoctocogene roxaparvovec for hemophilia A. Upcoming catalysts include clinical trial results for BMN 307 and BMN 255, which could expand BioMarin's therapeutic offerings. However, potential risks include regulatory hurdles, competition from other biotechnology companies, and the inherent challenges in developing and commercializing therapies for rare diseases. The company's gross margin of 75.9% indicates strong pricing power, but ongoing R&D expenses and market access challenges could impact future profitability.

Based on FMP financials and quantitative analysis

BMRN Key Highlights

Market capitalization of $12.7B, reflecting investor confidence in BioMarin's market position.

• P/E ratio of 40.23, indicating a premium valuation based on earnings expectations.
• Gross margin of 75.9%, showcasing strong pricing power and efficient cost management.
• Profit margin of 8.3%, demonstrating profitability in the competitive biotechnology industry.
• Beta of 0.29, suggesting lower volatility compared to the overall market.

Who Are BMRN's Competitors?

BMRN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BMRN's Key Strengths?

Strong portfolio of approved therapies for rare diseases.

• Expertise in enzyme replacement and gene therapy technologies.
• Global commercial presence and distribution network.
• Strong intellectual property protection.

What Are BMRN's Weaknesses?

High dependence on a limited number of products.

• Vulnerability to patent expirations and generic competition.
• High R&D expenses and clinical trial risks.
• Regulatory challenges and market access barriers.

What Could Drive BMRN Stock Higher?

Clinical trial results for BMN 307 in PKU patients expected in 2027.

• Potential regulatory approval and launch of valoctocogene roxaparvovec for hemophilia A by 2027.
• Clinical trial data for BMN 255 in primary hyperoxaluria anticipated in 2028.
• Continued expansion of Voxzogo's market share for achondroplasia treatment.
• Strategic partnerships and collaborations to enhance research and commercialization efforts.

What Are the Key Risks for BMRN?

Rich valuation — a P/E of 40.23 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Regulatory delays or rejection of valoctocogene roxaparvovec.
• Competition from other gene therapy developers in the hemophilia A market.
• Adverse clinical trial results for pipeline candidates.
• Patent expirations and generic competition for existing products.
• Market access challenges and reimbursement pressures in certain geographic regions.

What Are the Growth Opportunities for BMRN?

• Expansion of Voxzogo for Achondroplasia: Voxzogo, a once-daily injection for achondroplasia, represents a significant growth opportunity. The global market for achondroplasia treatment is estimated to reach $1 billion by 2028. BioMarin has the potential to expand its market share through increased awareness, broader geographic reach, and potential label expansions to include younger age groups. The timeline for further market penetration is ongoing, with continued efforts to educate healthcare providers and families about the benefits of Voxzogo.
• Valoctocogene Roxaparvovec for Hemophilia A: Valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, is a key growth driver. The hemophilia A market is valued at approximately $11 billion, and gene therapies are expected to capture a significant portion of this market. BioMarin anticipates potential regulatory approval and launch in major markets by 2027, offering a one-time treatment with the potential to significantly reduce or eliminate the need for regular factor VIII infusions. Successful commercialization could generate substantial revenue growth.
• Advancement of BMN 307 for PKU: BMN 307, an AAV5-mediated gene therapy for PKU, represents a promising growth opportunity. PKU affects approximately 1 in 10,000 newborns, and the current standard of care involves strict dietary restrictions and medication. BMN 307 aims to normalize blood Phe concentration levels, potentially offering a more convenient and effective treatment option. Phase 1/2 clinical trial results are expected in 2027, and positive data could accelerate development and regulatory approval.
• Development of BMN 255 for Primary Hyperoxaluria: BMN 255, currently in Phase 1/2 clinical trials for primary hyperoxaluria, is another potential growth driver. Primary hyperoxaluria is a rare genetic disorder that leads to kidney stones and kidney failure. The market for primary hyperoxaluria treatments is underserved, and BMN 255 could address a significant unmet medical need. Clinical trial data is anticipated in 2028, and positive results could lead to regulatory approval and commercialization.
• Geographic Expansion: BioMarin has the opportunity to expand its geographic presence, particularly in emerging markets. These regions often have limited access to specialized therapies for rare diseases, presenting a significant growth opportunity. By establishing partnerships, navigating regulatory pathways, and increasing awareness, BioMarin can tap into these markets and improve access to its therapies. This expansion is an ongoing process, with continuous evaluation of market opportunities and strategic partnerships.

What Threats Does BMRN Face?

• Competition from other biotechnology and pharmaceutical companies.
• Adverse clinical trial results.
• Changes in regulatory policies and reimbursement rates.
• Economic downturns and healthcare budget constraints.

What Are BMRN's Competitive Advantages?

• Patents and exclusivity on rare disease therapies.
• Specialized knowledge and expertise in rare disease research and development.
• Established relationships with key opinion leaders and patient advocacy groups.
• High barriers to entry due to regulatory requirements and clinical trial costs.
• Strong brand reputation and market presence in the rare disease space.

What Does BMRN Do?

BioMarin Pharmaceutical Inc., founded in 1996 and headquartered in San Rafael, California, is a biotechnology company dedicated to developing and commercializing therapies for individuals with serious and life-threatening rare diseases and medical conditions. The company's initial focus was on enzyme replacement therapies, addressing lysosomal storage disorders such as mucopolysaccharidosis (MPS). Its product portfolio includes Vimizim for MPS IV type A, Naglazyme for MPS VI, Kuvan for phenylketonuria (PKU), Palynziq for PKU, Brineura for ceroid lipofuscinosis type 2 (Batten disease), Voxzogo for achondroplasia, and Aldurazyme for alpha-L-iduronidase deficiency. These therapies are delivered through various methods, including enzyme replacement, subcutaneous injection, and oral administration. Over the years, BioMarin has expanded its research and development efforts to include gene therapies, aiming to provide more durable and potentially curative treatments. Key pipeline products include valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, currently in Phase III clinical trials; BMN 307, a gene therapy for PKU in Phase 1/2 clinical trials; and BMN 255, also in Phase 1/2 clinical trials for primary hyperoxaluria. BioMarin serves a global market, supplying specialty pharmacies, hospitals, government agencies, distributors, and pharmaceutical wholesalers in the United States, Europe, Latin America, and other international regions. The company has also established strategic collaborations and licensing agreements with companies like Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. to enhance its research and commercialization capabilities.

What Products and Services Does BMRN Offer?

• Develop and commercialize therapies for rare genetic diseases.
• Offer enzyme replacement therapies for lysosomal storage disorders.
• Provide treatments for metabolic disorders like phenylketonuria (PKU).
• Develop gene therapies for hemophilia A and other genetic conditions.
• Serve specialty pharmacies, hospitals, and government agencies globally.
• Engage in research and development to expand their product pipeline.
• Collaborate with other pharmaceutical companies to enhance research and commercialization.

How Does BMRN Make Money?

• Develop and patent novel therapies for rare diseases.
• Conduct clinical trials to demonstrate safety and efficacy.
• Obtain regulatory approvals from agencies like the FDA and EMA.
• Manufacture and distribute therapies globally.
• Generate revenue through product sales to hospitals, pharmacies, and government agencies.

What Industry Does BMRN Operate In?

BioMarin operates within the biotechnology industry, which is characterized by high growth potential and significant R&D investments. The market for rare disease therapies is expanding, driven by increased awareness, improved diagnostics, and regulatory incentives. Competition includes companies such as RVMD: Revolution Medicines, Inc., MRNA: Moderna, Inc., BBIO: BridgeBio Pharma, Inc., ALGN: Align Technology, Inc., and EXEL: Exelixis, Inc., all vying for market share in specialized therapeutic areas. BioMarin's focus on genetic and metabolic disorders positions it favorably within this landscape, particularly with its advancements in gene therapy.

Who Are BMRN's Key Customers?

• Patients with rare genetic diseases.
• Specialty pharmacies that dispense rare disease medications.
• Hospitals and medical centers that treat patients with rare diseases.
• Government agencies and healthcare providers.
• Distributors and pharmaceutical wholesalers.

BioMarin Pharmaceutical Inc. Financial Trajectory

BioMarin Pharmaceutical Inc. (BMRN) reported $989.7M in revenue for Jun 2026, reflecting 29.2% growth compared to the prior quarter. The company recorded net income of $44.8M, with diluted EPS of $0.23. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BMRN averaged $0.09 in diluted EPS.

Company Profile

BioMarin Pharmaceutical Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Rafael, US. The company is led by CEO Alexander Hardy. BMRN has traded publicly since 1999.

How BioMarin Pharmaceutical Inc. Is Valued

BioMarin Pharmaceutical Inc. carries a market capitalization of $12.7B, placing it in the large-cap category. Analyst price targets span from $59.00 to $124.00, with a consensus of $90.94. At the current price of $65.51, that implies approximately 39% upside potential. Relative to its peer group, BMRN's quantitative score of 65/100 is below the peer average of 78/100.

Return on equity for BioMarin Pharmaceutical Inc. stands at 4.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. BMRN trades at a trailing price-to-earnings ratio of 40.23, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.

BioMarin Pharmaceutical Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.02 places it in the grey zone, a middle ground that warrants monitoring.

BioMarin Pharmaceutical Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 15.4% below estimates on average.

Wall Street analysts project BioMarin Pharmaceutical Inc. revenue of about $3.91B for fiscal 2026, with EPS near $5.03. The estimate reflects 19 contributing analysts.

Over the past six months, BioMarin Pharmaceutical Inc. insiders filed 31 SEC Form 4 transactions — 10 sales and 21 purchases. On net that is roughly 457K shares acquired (about $13.9M) — insiders putting money in tends to read as conviction.

BMRN Financials

BMRN Latest News

BMRN Analyst Consensus

BMRN MoonshotScore

Latest BioMarin Pharmaceutical Inc. Analysis

What Investors Ask About BioMarin Pharmaceutical Inc. (BMRN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources